Core Viewpoint - Guichuang Tongqiao (02190) is covered for the first time by Guotai Junan with a "Buy" rating, predicting EPS for 2025-2027 to be 0.70/0.89/1.14 CNY, and setting a target price of 33.5 CNY/36.4 HKD based on a 48X PE for 2025 [1] Group 1: Product and Market Positioning - The company focuses on peripheral and neurovascular interventional medical devices, establishing a comprehensive product pipeline with 73 products and R&D projects as of August 2025, of which 51 have received NMPA approval and 8 have EU CE certification [1] - The company has effectively capitalized on centralized procurement opportunities, leading to rapid revenue growth due to its deep platform layout [1] Group 2: Commercialization and Sales Growth - Since the launch of a major product at the end of 2020, the company has built a wide distribution network covering over 3,000 hospitals, with significant sales growth in neurovascular and peripheral vascular interventions [1] - In the first half of 2025, sales revenue for neurovascular intervention products increased by 25.0% year-on-year, while peripheral vascular intervention products saw a 46.2% increase [1] Group 3: International Expansion - The company's international business grew by 36.9% year-on-year in the first half of 2025, primarily driven by markets in Europe and Asia [2] - The company has established sales of 22 products across 27 overseas countries/regions, with a focus on penetrating markets in France, Germany, and Italy, as well as expanding into emerging markets like Brazil, India, and South Africa [2] - Strategic partnerships with over 60 local partners have enabled the company to cover channels in 52 countries and regions globally [2]